ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: A systematic review

You, Xiangyun; Huang, Shan; Wang, Xin'an; Yi, Cheng; Gong, Niandong; Yu, Junfeng; Xu, Chengdang*; Xiang, Zhendong*同济大学; 1
Frontiers in Endocrinology2023-4-11DOI: 10.3389/fendo.2022.1125838
1被引9阅读
引用收藏
分享

摘要

Bipolar androgen therapy (BAT) is a new endocrinologic treatment for castration-resistant prostate cancer (CRPC) that can restore some patients' sensitivity to drugs such as abiraterone (Abi) and enzalutamide (Enz). We performed a meta-analysis using STATA16. Sensitivity analyses were performed by examining the effects of individual studies using different effect models and detecting any publication bias using the Harbord test. In a total of 108 unique records, ten studies were included in the final meta-analysis. Participants who underwent BAT achieved a PSA50 response rate of 27% (95%CI [0.22,0.31], I2=17.98%), ORR of 34% (95%CI [0.24,0.43], I2=0), and incidence of AEs (grade >= 3) of 14% (95%CI [0.09,0.19], I2=0). Patients who completed BAT proceeded to AR-targeted therapy (Abi or Enz) and achieved a PSA50 response rate of 57% (95% CI [0.36,0.78], I2=0). Patients with prior Enz resistance had a stronger impact on the PSA50 of AR-target therapy rechallenge. The results of this meta-analysis indicate that BAT is a safe and effective treatment for patients who have progressed after Abi or Enz. BAT can trigger the resensitization of patients with CRPC to subsequent endocrine therapy and improve the overall survival of patients and their quality of life.

学科与关键词

关键词
bipolar androgen therapytestosteronecastration-resistant prostate cancerabirateroneenzalutamide
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Frontiers in Endocrinology
发表日期
2023-04-11
卷期
第 13 卷
页码
1125838
DOI
10.3389/fendo.2022.1125838
成果收录
SCIE

作者

  • Y

    You, Xiangyun (第一作者)

    1 · china three gorges univ

  • H

    Huang, Shan

    1 · china three gorges univ

查看全部 8 位作者收起作者
  • W

    Wang, Xin'an

    tongji univ

  • Y

    Yi, Cheng

    1 · china three gorges univ

  • G

    Gong, Niandong

    1 · china three gorges univ

  • Y

    Yu, Junfeng

    1 · china three gorges univ

  • X

    Xu, Chengdang (通讯)

    tongji univ

  • X

    Xiang, Zhendong (通讯)

    1 · china three gorges univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417